isoxazoles has been researched along with gefitinib in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sipp, D | 1 |
Kudo, S | 1 |
Chida, K; Miyazaki, K; Ogura, T; Sugiyama, Y; Yamaguchi, T | 1 |
Clarke, AR; Maughan, TS; Shaw, PH | 1 |
Asano, H; Furukawa, M; Hashida, S; Kanazawa, S; Maki, Y; Miyoshi, S; Ohtsuka, T; Shien, K; Soh, J; Suzawa, K; Toyooka, S; Tsukuda, K; Yamamoto, H | 1 |
Baek, IJ; Bivona, TG; Choi, CM; Choi, SH; Choi, YJ; Kim, SY; Kim, WS; Lee, JC; Rho, JK; So, KS | 1 |
Chen, DQ; Ding, J; Geng, MY; Liu, HC; Shen, AJ; Shen, JK; Sun, JY; Wang, X; Wang, YQ; Xiong, B; Zhang, MM; Zheng, M | 1 |
1 review(s) available for isoxazoles and gefitinib
Article | Year |
---|---|
[Drug induced lung injuries in Japanese population].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Asian People; Bleomycin; Gefitinib; Genetic Predisposition to Disease; Humans; Isoxazoles; Japan; Leflunomide; Lung Diseases, Interstitial; Pulmonary Alveoli; Quinazolines; Racial Groups | 2006 |
6 other study(ies) available for isoxazoles and gefitinib
Article | Year |
---|---|
'Fast-track' drug approvals hit speed bumps in Japan.
Topics: Drug Approval; Drug Evaluation; Gefitinib; Isoxazoles; Japan; Leflunomide; Public Policy; Quinazolines | 2004 |
[Diagnosis of and therapy for diffuse lung diseases (discussion)].
Topics: Alveolitis, Extrinsic Allergic; Biomarkers; Bronchiolitis; Gefitinib; Humans; Isoxazoles; Leflunomide; Lung Diseases, Interstitial; Quinazolines; Sarcoidosis, Pulmonary; Tomography, X-Ray Computed | 2006 |
Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.
Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Down-Regulation; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Gefitinib; Genes, APC; Intestinal Neoplasms; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, IGF Type 1; Tumor Burden | 2011 |
Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA End-Joining Repair; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Resorcinols | 2015 |
AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
Topics: Animals; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice, SCID; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Resorcinols; Xenograft Model Antitumor Assays | 2015 |
Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Heterografts; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasm Transplantation; Oxazoles; Quinazolines; Resorcinols | 2016 |